Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.43 EUR+3.32 %7.10, 17.29
5,663 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+3.32 %
-12.68 %
-16.45 %
-40.58 %
-62.02 %
-62.66 %
-41.31 %
-85.56 %
-68.73 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
30.78M EUR
Turnover
57.34K EUR
P/E (adj.) (26e)
-11.31
EV/EBIT (adj.) (26e)
-7.92
P/B (26e)
1.44
EV/S (26e)
1.47
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
17.08.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Topcon spinnaa ulos Oku Digital Healthin, käytännössä jättimäisen silmän kuvantamiseen perustuvan digitaalisen terveysalustan. Pohjalla on jo yli 10 000 connected care -pistettä, 50 000+ Topcon-laitteen asennuskanta ja 2,2 miljoonaa perinteisen silmäterveydenhuollon ulkopuolella ...
11 hours ago
by Puutaheinää
44
The US and those 100,000 clinics sound pretty nice, but it doesn’t quite match China in sheer numbers Just as a refresher, here’s a copy of Wiser’s post that was shared on the forum earlier. “”“”“”“”“” China has 1.05 million primary healthcare institutions. 560,000 village clinics...
5 hours ago
by j.sälli
18
Käänne ei ole mikään ajallisesti tarkkaan rajattu tapahtuma. Nyt ollaan kasvussa (puheiden mukaan) tärkeimmällä AEYE markkinalla, Lumossa viriää myös (ilmeisesti) ainakin Euroopassa kiinostus. Niin kauan kuin on kasvua RR bisneksessä (toivottavasti sitä jo on) jatkuu aikatauluni ...
10/5/2026, 6:32 AM
by Puutaheinää
10
Mielenkiinnosta kysyn, että onko teillä tähän merkittävästi sijoittaneilla joku aikataulu jonka puitteissa luvuissa havaittavan käänteen täytyy tapahtua? Q3? Q4? Ymmärrän, että toiveikkuus kuuluu asiaan mutta olen havaitsevinani tällä palstalla myös osakkeen kanssa naimisissa oloa...
10/5/2026, 5:56 AM
4
Kurssi ei määrää miten firma kehittyy, menee toisin päin tämä syy-seuraussuhde. Joku/jotkut omistajat luopuvat, epälikvidi yhtiö, ja kuten saamme lukea näiltä foorumeilta lasku aikaansaa pelkoa että firmassa on jotain vinossa, karkottaen ostajat. Jäitä hattuihin. Linkkarin mukaan...
10/5/2026, 5:37 AM
by Puutaheinää
4
Q3 kertoo todella paljon kehityksestä. Vaikka ois hitaita myyntisyklejä jenkeissä public sectorilla, niin pitäisi pikkuhiljaa rueta näkymään lv+tuloksessa.
10/5/2026, 5:46 AM
by Kotjrvi
3
Yes, but not at the expense of burning through cash. Optomed is of course aiming for a streamlined regulatory process in the US—after all, Lumo is an evolved model from Aurora—but they shouldn’t rush into any multi-million euro validation studies. Not until cash flow has been proven...
2 hours ago
by Dr.Feelgood
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.11
2026

Interim report Q3'26

18.2
2027

Annual report '26

4.5
2027

Interim report Q1'27

Regulatory press release07.10.2026, 13.00

Optomed Oyj: Disclosure under Chapter 9, Section 10 of the Securities Markets Act regarding change in holdings

Optomed
Regulatory press release28.09.2026, 15.17

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.15

Optomed Oyj - Managers' Transactions - Piila

Optomed
Regulatory press release28.09.2026, 15.12

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.10

Optomed Oyj - Managers' Transactions - Myllylä

Optomed
Regulatory press release28.09.2026, 15.07

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.05

Optomed Oyj - Managers' Transactions - Knuutti

Optomed
Regulatory press release28.09.2026, 15.01

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release28.09.2026, 15.00

Optomed Oyj - Managers' Transactions - Himberg

Optomed
Regulatory press release25.09.2026, 14.30

Optomed Oyj: Optomed's Board of Directors has resolved to establish a new stock option plan

Optomed
Optomeds dattercelskab Ubetec har vundet Veikkauses udbud
Analyst Comment07.09.2026, 06.55 by
Juha Kinnunen

Optomeds dattercelskab Ubetec har vundet Veikkauses udbud

Veikkaus' kontraktsejr på 0,9 MEUR styrker datterselskabet Ubetecin position på det åbne finske spillegældsmarked.

Optomed
Regulatory press release04.09.2026, 14.00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed